References
- Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013; 63:249-279.
- Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011; 65:624-635.
- Hashimoto H, Ito T, Ichiki T, et al. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes. J Clin Med. 2021;10(4):728.
- Cairns P. Renal cell carcinoma. Cancer Biomark. 2010; 9(1-6):461-73.
- Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016; 9:45-52.
- Méndez-Vidal MJ, Molina Á, Anido U, et al. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol. 2018;19(1):77.
- Deng J, Li L, Xia H, et al. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis. Medicine (Baltimore). 2019;98(27):e16309.
- Mancini M, Righetto M, Baggio G. Gender-Related Approach to Kidney Cancer Management: Moving Forward. Int J Mol Sci. 2020;21(9)
- Chu CH, Chou CY, Lin FL. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment. J Eur Acad Dermatol Venereol. 2016;30(10):e81-e83.
- Vale EPBMD, Rodrigues CHL, Kallas FE, et al. Eczema craquelé associated with antiviral treatment for chronic hepatitis C. An Bras Dermatol. 2017;92(3):436-437.
- Boers-Doets C, Lacouture M, Langenhoff J, et al. Interventions for skin reactions associated with targeted anti-cancer treatments. Cochrane Database of Systemic Reviews. 2011.
- McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatologic Therapy. 2011; 24:396–400.
- Ng SY, Begum S, Chong SY. Does Order of Application of Emollient and Topical Corticosteroids Make a Difference in the Severity of Atopic Eczema in Children? Pediatr Dermatol. 2016;33(2):160-4.
- Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531-7.
- Schulz P, Bunselmeyer B, Bräutigam M, et al. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007;21(1):90-4.